Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Muralikrishnan Parthasarathy

Psychiatry Vista, CA Medical Doctor

NPI 1952569063 CMS profile 88645

2120 Thibodo Rd, Ste# 230, Vista, CA 92081

Open in the dashboard

General payments

$3,557

220 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Muralikrishnan Parthasarathy of Vista, CA is reported in the CMS Open Payments database as having received $3,557 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $15 1
2022 General $874 43
2021 General $519 26
2020 General $613 33
2019 General $1,537 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muralikrishnan Parthasarathy
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Muralikrishnan Parthasarathy were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Muralikrishnan Parthasarathy Psychiatry median Middle half National median
2019 $1,537 $184 $59–$605 $163
2020 $613 $119 $36–$372 $114
2021 $519 $143 $43–$576 $132
2022 $874 $153 $50–$590 $149
2023 $15 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Sunovion Pharmaceuticals Inc. $1,125 62 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $541 32 payments
  3. Lundbeck LLC $351 30 payments
  4. Janssen Pharmaceuticals, Inc $303 15 payments
  5. Otsuka America Pharmaceutical, Inc. $259 15 payments
  6. Tris Pharma Inc $211 18 payments
  7. Ironshore Pharmaceuticals Inc. $205 11 payments
  8. Allergan Inc. $165 16 payments
  9. Neurocrine Biosciences, Inc. $112 6 payments
  10. Vanda Pharmaceuticals Inc. $95 5 payments
  11. Other $191 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,551 219 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2023
  1. LATUDA $1,125 62 payments
  2. REXULTI Psychiatry $265 21 payments
  3. REXULTI Psychiatry $259 15 payments
  4. INVEGA SUSTENNA $228 10 payments
  5. SPRAVATO $217 10 payments
  6. INVEGA TRINZA $196 8 payments
  7. TRINTELLIX $192 10 payments
  8. VYVANSE $169 10 payments
  9. VRAYLAR $165 16 payments
  10. JORNAY PM $163 8 payments
  11. Other $1,126 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

512

Median for Psychiatry: 574

Drug cost

$12,225

Median for Psychiatry: $27,624

Branded share of claims

23.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 17 $2,697
Bupropion Xl Bupropion Hcl Brand 45 $1,751
Divalproex Sodium Er Divalproex Sodium Brand 12 $1,213
Olanzapine Generic 35 $923
Bupropion Hcl Sr Bupropion Hcl Brand 12 $741
Lamotrigine Generic 39 $602
Quetiapine Fumarate Generic 13 $586
Hydroxyzine Hcl Generic 27 $546
Venlafaxine Hcl Er Venlafaxine Hcl Brand 15 $529
Aripiprazole Generic 15 $491

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$4,810

Medicare's payments for the services billed

Medicare patients

22

Average age 60

Services billed

67

11 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 50%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record